Acute lymphoblastic leukemia (ALL) represents around 70% of pediatric leukemia. In high-income countries, the 5-year survival is above 90%, but survival in low- and middle-income countries is inferior ...

What Is Acute Lymphoblastic Leukemia? Acute lymphoblastic leukemia (ALL) is a type of blood cancer that starts in white blood cells in your bone marrow, the soft inner part of your bones. It develops ...

Haplo-cord HCT offered improved 2-year OS (72.7% vs 61.0%) and DFS (67.0% vs 49.6%) compared with haplo HCT alone.

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

A new cell therapy, targeting CD7 on leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment ...

The FDA has issued a complete response letter (CRL) to a new drug application (NDA) for Dasynoc for the treatment of chronic ...

Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia with a poor prognosis in adults. 1 The current foundational treatment is intensive, long-term chemotherapy. 2 In 2017, it is ...

A 12-year-old girl diagnosed with acute lymphoblastic leukemia was successfully treated for the first time with CAR-T immune cell therapy by doctors at the Ho Chi Minh City Blood Transfusion and ...

The Company has submitted a supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA has been granted Priority Review by the FDA and ...